At the pulse of heart disease

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.


CDR132L featured in Nature Reviews Genetics

Cardior’s lead candidate CDR132L is featured in the article “Non-coding RNAs in disease: from mechanisms to therapeutics” published in Nature Review Genetics on November 15, 2023. The article by Kinga Nemeth, Recep Bayraktar, Manuela Ferrachin, and George Calin offers a comprehensive summary of our current knowledge of noncoding RNAs and of their roles in major human diseases. It discusses the potential use of RNAs as disease biomarkers and therapeutic targets and lists the most notable clinical research in the field to date.

42nd Annual J.P. Morgan Healthcare Conference
BioCapital Europe